Evolus Announces CFO Departure, New CMO & Board Members
Ticker: EOLS · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1570562
| Field | Detail |
|---|---|
| Company | Evolus, INC. (EOLS) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, cfo-departure, board-election, officer-appointment
TL;DR
Evolus CFO out, new interim CMO and board members in. Big changes at the top.
AI Summary
Evolus, Inc. announced on June 6, 2024, the departure of its Chief Financial Officer, Michael J. MacBride, effective June 14, 2024. The company also appointed Dr. David J. Stark as interim Chief Medical Officer and announced the election of two new directors, Dr. David J. Stark and Ms. Michelle L. R. Smith, to its Board of Directors.
Why It Matters
This filing indicates significant leadership changes within Evolus, including the departure of its CFO and the appointment of new interim CMO and board members, which could impact the company's strategic direction and financial oversight.
Risk Assessment
Risk Level: medium — Leadership changes, especially the CFO's departure, can introduce uncertainty regarding financial strategy and operational stability.
Key Players & Entities
- Evolus, Inc. (company) — Registrant
- Michael J. MacBride (person) — Departing Chief Financial Officer
- June 14, 2024 (date) — Effective date of CFO departure
- Dr. David J. Stark (person) — Appointed Interim Chief Medical Officer and Elected Director
- Ms. Michelle L. R. Smith (person) — Elected Director
- June 6, 2024 (date) — Date of Report
FAQ
Who is replacing Michael J. MacBride as Chief Financial Officer?
The filing does not specify a permanent replacement for Michael J. MacBride; Dr. David J. Stark has been appointed interim Chief Medical Officer.
When is Michael J. MacBride's departure effective?
Michael J. MacBride's departure is effective June 14, 2024.
Who are the new members of the Board of Directors?
The new members elected to the Board of Directors are Dr. David J. Stark and Ms. Michelle L. R. Smith.
What is Dr. David J. Stark's role in addition to being a new board member?
Dr. David J. Stark has also been appointed as the interim Chief Medical Officer.
What is the company's principal executive office address?
The company's principal executive offices are located at 520 Newport Center Drive, Suite 1200, Newport Beach, California 92660.
Filing Stats: 950 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2024-06-11 16:05:21
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share EOLS The Nasdaq Stock Market
Filing Documents
- eols-20240606.htm (8-K) — 45KB
- eols2024espp.htm (EX-10.1) — 106KB
- 0001570562-24-000098.txt ( ) — 299KB
- eols-20240606.xsd (EX-101.SCH) — 2KB
- eols-20240606_lab.xml (EX-101.LAB) — 23KB
- eols-20240606_pre.xml (EX-101.PRE) — 13KB
- eols-20240606_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. At the Annual Meeting, the stockholders of the Company voted on five proposals as further described in the 2024 Proxy. The results for each matter voted on by the stockholders at the Annual Meeting were as follows: Proposal 1 : The stockholders of the Company elected each of David Moatazedi, Vikram Malik and Karah Parschauer as Class III Directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal. The results of the stockholders' vote with respect to the election of the Class III Directors were as follows: Nominee Term Expiring For Withhold Broker Non-Vote David Moatazedi 2027 35,760,304 315,672 10,304,558 Vikram Malik 2027 28,520,526 7,555,450 10,304,558 Karah Parschauer 2027 27,566,427 8,509,549 10,304,558 Proposal 2 : The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. The results of the stockholders' vote with respect to such ratification were as follows: For Against Abstain 46,266,815 90,103 23,616 Proposal 3 : The stockholders of the Company approved the ESPP. The results of the stockholders' vote with respect to the approval of the ESPP were as follows For Against Abstain Broker Non-Vote 26,223,926 9,653,206 198,844 10,304,558 Proposal 4 : The stockholders of the Company approved, on an advisory basis, the compensation of the Company's named executive officers. The results of the stockholders' vote with respect to the approval, on an advisory basis of the Company's named executive officers were as follows For Against Abstain Broker Non-Vote 32,828,722 3,036,818 210,436 10,304,558 Proposal 5 : The stockholder of the company approved, on a non-binding basis, one year to be the frequency of
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Evolus Inc. 2024 Employee Stock Purchase Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Evolus, Inc. Dated: June 11, 2024 /s/ David Moatazedi David Moatazedi President and Chief Executive Officer